ALLMedicine™ Hidradenitis Suppurativa Center
Research & Reviews 2,679 results
https://doi.org/10.1111/ijd.15459
International Journal of Dermatology; Jørgensen AR, Yao Y et. al.
Mar 4th, 2021 - To evaluate the clinical efficacy of tetracycline, doxycycline, and lymecycline in patients with hidradenitis suppurativa (HS). A prospective study of three different treatment regimens in patients with HS; oral tetracycline 500 mg twice daily, or...
https://doi.org/10.1016/j.jaad.2021.02.066
Journal of the American Academy of Dermatology; Jfri A, Litvinov IV et. al.
Mar 4th, 2021 - Clinical and psychosocial factors affecting work productivity among patients with hidradenitis suppurativa: A cluster analytical investigation.|2021|Jfri A,Litvinov IV,Netchiporouk E,O'Brien E,|
https://doi.org/10.1111/dth.14919
Dermatologic Therapy; Iannone M, Janowska A et. al.
Feb 26th, 2021 - The combination of oral clindamycin with rifampicin is recommended by European guidelines as a first-line treatment in moderate-to-severe hidradenitis suppurativa (HS). Recent studies highlight that oral clindamycin in monotherapy may be a useful ...
https://doi.org/10.1080/14737167.2021.1895753
Expert Review of Pharmacoeconomics & Outcomes Research; Gáspár K, Hunor Gergely L et. al.
Feb 25th, 2021 - Background: Hidradenitis suppurativa (HS) is a potentially disabling, chronic inflammatory skin disease affecting up to 1% of the population in Europe. This study aims to assess the cost-of-illness of HS from a societal perspective in Hungary, and...
https://doi.org/10.1111/1346-8138.15797
The Journal of Dermatology; Moltrasio C, Tricarico PM et. al.
Feb 24th, 2021 - 25-Hydroxyvitamin D serum levels inversely correlate to disease severity and serum C-reactive protein levels in patients with hidradenitis suppurativa.|2021|Moltrasio C,Tricarico PM,Genovese G,Gratton R,Marzano AV,|
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.
Nov 4th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...
Clinicaltrials.gov 2,901 results
https://doi.org/10.1111/ijd.15459
International Journal of Dermatology; Jørgensen AR, Yao Y et. al.
Mar 4th, 2021 - To evaluate the clinical efficacy of tetracycline, doxycycline, and lymecycline in patients with hidradenitis suppurativa (HS). A prospective study of three different treatment regimens in patients with HS; oral tetracycline 500 mg twice daily, or...
https://doi.org/10.1016/j.jaad.2021.02.066
Journal of the American Academy of Dermatology; Jfri A, Litvinov IV et. al.
Mar 4th, 2021 - Clinical and psychosocial factors affecting work productivity among patients with hidradenitis suppurativa: A cluster analytical investigation.|2021|Jfri A,Litvinov IV,Netchiporouk E,O'Brien E,|
https://doi.org/10.1111/dth.14919
Dermatologic Therapy; Iannone M, Janowska A et. al.
Feb 26th, 2021 - The combination of oral clindamycin with rifampicin is recommended by European guidelines as a first-line treatment in moderate-to-severe hidradenitis suppurativa (HS). Recent studies highlight that oral clindamycin in monotherapy may be a useful ...
https://doi.org/10.1080/14737167.2021.1895753
Expert Review of Pharmacoeconomics & Outcomes Research; Gáspár K, Hunor Gergely L et. al.
Feb 25th, 2021 - Background: Hidradenitis suppurativa (HS) is a potentially disabling, chronic inflammatory skin disease affecting up to 1% of the population in Europe. This study aims to assess the cost-of-illness of HS from a societal perspective in Hungary, and...
https://doi.org/10.1111/1346-8138.15797
The Journal of Dermatology; Moltrasio C, Tricarico PM et. al.
Feb 24th, 2021 - 25-Hydroxyvitamin D serum levels inversely correlate to disease severity and serum C-reactive protein levels in patients with hidradenitis suppurativa.|2021|Moltrasio C,Tricarico PM,Genovese G,Gratton R,Marzano AV,|
News 265 results
https://www.medscape.com/viewarticle/945207
Feb 2nd, 2021 - Delaying surgical reconstruction of fistula structures until after patients with hidradenitis suppurativa (HS) have been on adalimumab for a minimum of 6 months transforms primary wound closure into a highly attractive option, a pilot study sugges...
https://www.medscape.com/viewarticle/944781
Jan 26th, 2021 - A once-daily oral selective Janus kinase 1 inhibitor demonstrated promising safety and efficacy for the treatment of moderate to severe hidradenitis suppurativa (HS) in a pair of small, randomized, phase 2 studies that established proof-of-concept...
https://www.staging.medscape.com/viewarticle/932882
Jun 23rd, 2020 - Young men with hidradenitis suppurativa are "surprisingly" at increased risk for hypothyroidism, Anna Figueiredo, MD, declared at the virtual annual meeting of the American Academy of Dermatology. The surprise about this finding from a large retro...
https://www.medscape.com/viewarticle/932882
Jun 23rd, 2020 - Young men with hidradenitis suppurativa are "surprisingly" at increased risk for hypothyroidism, Anna Figueiredo, MD, declared at the virtual annual meeting of the American Academy of Dermatology. The surprise about this finding from a large retro...
https://www.medscape.com/viewarticle/931544
Jun 3rd, 2020 - NEW YORK (Reuters Health) - Hidradenitis suppurativa (HS) was associated with an increased risk of cancer in a population-based study in Korea. Dr. Mi Woo Lee of the University of Ulsan College of Medicine in Seoul investigated overall and specifi...